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Abstract
Translating policy into action is a complex task, with much debate surrounding the process whereby US and Canadian
health funding agencies intend to integrate sex and gender science as an integral component of methodological rigor
and reporting in health research. Effective January 25, 2016, the US National Institutes of Health implemented a policy
that expects scientists to account for the possible role of sex as a biological variable (SABV) in vertebrate animal and
human studies. Applicants for NIH-funded research and career development awards will be asked to explain
how they plan to factor consideration of SABV into their research design, analysis, and reporting; strong
justification will be required for proposing single-sex studies. The Canadian Institutes of Health Research is
revising their peer review accreditation process to ensure that peer reviewers are skilled in applying a critical
lens to protocols that should be incorporating sex and gender science. The current paper outlines the
components that peer reviewers in North America will be asked to assess when considering whether SABV is
appropriately integrated into research designs, analyses, and reporting. Consensus argues against narrowly
defining rules of engagement in applying SABV, with criteria provided for reviewers as guidance only. Scores
will not be given for each criterion; applications will be judged on the overall merit of scientific innovation,
rigor, reproducibility, and potential impact.
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Background
In May 2014, the US National Institutes of Health
announced a policy aimed at integrating sex as a biological
variable (SABV) into biomedical research [1]. The an-
nouncement led to a spirited debate in the scientific litera-
ture and popular press on the subject of promoting due
diligence in exploring sex differences while respecting the
principles of scientific freedom [2–5]. Our objective here
is to describe the decisions taken by two major North
American health funding agencies, the US National Insti-
tutes of Health (NIH) and the Canadian Institutes of Health
Research (CIHR), for applying metrics to evaluate SABV by
peer reviewers in their respective organizations [1, 6].
Main text
In order to determine the preferred scoring method to
gauge the appropriateness of SABV in research protocols
involving preclinical studies with vertebrate animal and
humans, an iterative process was undertaken by both
the NIH and CIHR. The NIH’s Office of Research on
Women’s Health championed the process in the USA,
with SABV being considered as only one element of a
broad NIH initiative to enhance rigor, transparency, and
reproducibility of preclinical biomedical research [7].
The Institute of Gender and Health championed SABV on
behalf of the CIHR, as part of the Canadian federal gov-
ernment’s Health Portfolio policy on sex-and-gender-
based analysis [8]. Two independent champions, two dif-
ferent policies, yet the selection of metrics for the evalu-
ation of SABV ended up being remarkably similar for
both funding agencies. The process consisted of (a) an en-
vironmental scan of the literature for critical components
of SABV; (b) key informant consultations and stakeholder
forums; and (c) high-level discussions by decision-makers
inside each funding organization. In February 2015, the
US Office of Research on Women’s Health and Canada’s
Institute of Gender and Health compared notes. They
then created a consensus list of 13 evaluation criteria that
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might be used as a minimal standard for peer reviewers
evaluating SABV information.
As part of the feedback process on the evaluation criteria,
the Organization for the Study of Sex Differences (OSSD)
anonymously surveyed health researchers who had regis-
tered for its 2015 annual meeting on their perceptions of
the importance of including each of these elements in a
peer review rating scale for SABV. Figure 1 illustrates the
proportion of online survey respondents (n = 30) who
assessed each of the 13 evaluation criteria as being abso-
lutely critical, rather critical, important but not critical, or
somewhat important/not critical in the assessment of
SABV. Seventy-five researchers then participated in a stake-
holder’s forum held at the OSSD meeting on April 21,
2015, in Palo Alto, CA, to discuss and vote on issues that
generated the most diverse responses in the initial survey.
Participants were international, originating from Canada,
South America, Europe, and Australia, with a majority rep-
resentation from the USA. Almost three quarters of re-
spondents considered themselves well versed in the study
of sex differences. Sixty-seven percent stated they studied
sex differences for 6 years or more. The distribution of re-
sponses shown in Fig. 1 is found to be representative of the
response of the larger group of 75 people at the stake-
holder’s forum.
The majority of participants proposed that peer re-
viewers should use the evaluation criteria as a SABV
checklist guide only and that individual scores not be
assigned to each criterion. Respondents expressed a
strong preference for incorporating the SABV rating
into the overall scientific evaluation of the research
protocol without asking peer reviewers to provide a
separate SABV score. Only one third of participants
preferred that the quality of SABV be rated independ-
ently but still be factored into the overall evaluation
score.
These results were considered in parallel to other
stakeholder consultations and independent discussion
with decision-makers at the NIH and CIHR. The verdict
fell concurrently for both organizations that no specific
score would be attributed to the integration of SABV in
research protocols. Consensus argued against narrowly
defining rules of engagement in applying SABV, as dis-
agreement exists even within the OSSD community on
gold standard criteria for assessment. SABV evaluation
criteria will be promoted as a guide for peer reviewers
when assessing the overall scientific merit of the applica-
tion, as regards scientific innovation, rigor, reproducibil-
ity, and expected impact. The CIHR’s reviewer checklist
can be found online [9]. Table 1 illustrates the key
Fig. 1 Ranking of the 13 SABV evaluation criteria according to the respondents’ assessment of absolutely critical or rather critical
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questions peer reviewers are encouraged to ask when de-
termining the overall score for the application.
To assist peer reviewers in acquiring competency to
evaluate SABV, the CIHR’s Institute of Gender and
Health developed an online training module in Septem-
ber 2015 to enable critical appraisal of the appropriate
integration, or omission, of SABV in research protocols
[10]. This module also aims to fill a gap in knowledge
and skills for the 60–80 % of the CIHR biomedical re-
searchers who, during mandatory reporting, indicated
that they do not integrate sex or gender into their re-
search designs [11]. The NIH’s Office of Research on
Women’s Health similarly held a method workshop and
posted an online report to assist scientists debuting the
integration of SABV in their research programs [12].
Concerns remain that integrating SABV into research
programs may be costly, that resources may not be avail-
able, and that duplication of all experimental procedures
in both sexes may be onerous and burdensome. If the
NIH and CIHR were truly advocating that equal num-
bers of males and females be included in all studies, then
this concern would be valid. However, the NIH and
CIHR advocate no such blind change in protocol. In-
stead, researchers and peer reviewers are being asked to
thoughtfully consider whether a single-sex study is justi-
fied when research results are to be applied to both
sexes. Funding organizations recognize that new, poten-
tially transformative discoveries such as one by a Canad-
ian researcher showing that chronic pain is mediated by
different immune cells in males and females will only be
brought about by funding studies that attempt to explain
sexually dimorphic discrepancies in the epidemiology of
disease or response to treatment [13]. By using scientific
acumen, researchers are given the freedom to decide if
and how SABV may be relevant to their field of study.
Will the answer sometimes require researchers to ask
for larger budgets for their studies to include equal
numbers of males and females? Absolutely. However, if
well justified, both the NIH and CIHR believe that the
investment in balancing the sexes will be worthwhile.
The topic of statistical power necessary to detect sex
differences continues to generate controversy, as does
the criticism that policies linked to SABV ignore the
contribution of other social determinants of health such
as gender, education, and socioeconomic status as risk
factors for disease [14–16]. Both the NIH and CIHR
recognize that animal models are not the panacea to
cure all human suffering. Both organizations simultan-
eously fund clinical, health systems and population
health research to address these questions. With respect
to sample size, what is clear is that sample size and
power for preclinical studies ultimately depend on the
specific question being posed by the researcher. It would
be inherently challenging to uniformly implement sam-
ple size requirements for SABV across the research
spectrum. Discretion will therefore be left to the re-
searcher to justify the sample size required for any given
research approach using SABV. Peer reviewers will be
asked to weigh in on whether the calculations make
sense, in the same way that sample size has been evalu-
ated in the past. No specific score will be recorded for
this element.
Conclusion
The NIH and CIHR intend that peer reviewers should
be given the instruction to make sure SABV is
accounted for in research design, analysis, and reporting
and, if only one sex will be used, that this is well justi-
fied. Evaluation of SABV is expected to depend on the
best judgment of the reviewers along with other criteria
used to assess the scientific excellence of a given pro-
posal. The research question at hand and the specific
scientific context should guide appropriate consideration
of SABV in a project, with the understanding that trans-
parency is crucial to building a sex-specific evidence
base.
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Table 1 Questions reviewers should consider when evaluating
SABV
Research approach for SABV
• Clarity of the research question.
• Clarity of rationale for the research approach and methodology.
• Appropriateness of the research design.
• Appropriateness of the research methods.
• Feasibility of the research approach.
• Anticipation of difficulties that may be encountered in the research
and plans for management.
• Quality and appropriateness of SABV.
• Justification for a single-sex study.
• Evidence that the research question incorporates SABV.
• Potential for the research to add value to the current state of knowledge
on a given topic that has potential to, but has not yet fully elucidated the
impact of sex on biological mechanisms, pathophysiology or translational
science.
Impact of research incorporating SABV
• Potential for a significant contribution to the improvement of women
and men’s health, the health of boys and girls, or the health of gender-
diverse persons.
• Appropriateness and adequacy of the proposed plan for knowledge
dissemination and exchange.
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